Comparing the current results to its competitors, Akari Therapeutics Plc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 32.44 %, recorded in the same quarter.
Akari Therapeutics Plc, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 95.09 %
Akari Therapeutics Plc's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, focusing on the oncology subsector. This sector is characterized by rapid technological change, intense competition, and strong protection of intellectual property. The company competes with larger, better-funded biotechnology and pharmaceutical firms, academic institutions, governmental agencies, and both public and private research organizations. It also faces competition from smaller or early-stage companies, universities, and other research institutions developing cancer therapeutics. Its product candidates may compete with existing and emerging therapies, including surgery, radiation, chemotherapy, hormone therapy, biologic therapies such as monoclonal and bispecific antibodies, immunotherapy, cell-based therapy, and targeted therapy. Competition extends across the oncology market for cost-effective and reimbursable cancer treatments. Market acceptance and achieving significant market share may be challenging due to competition and preferences by insurers or reimbursement authorities for generic or specific branded products. Bayer Pharmaceuticals is identified as a competitor in the company's filings.
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Sources:
Akari Therapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Akari Therapeutics Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
